Related by context. All words. (Click for frequent words.) 67 CARE HF 67 Clinical Antipsychotic Trials 66 number NCT# ClinicalTrials.gov 66 ENESTnd 65 Phase IIb III 65 ExTRACT TIMI 65 ONTARGET 65 randomized controlled multicenter 65 Intervention Effectiveness 64 Phase 1a clinical 64 multicenter Phase II 64 Pre Exposure Prophylaxis 64 Phase Ib II 64 Randomized controlled 64 ACCORD Lipid 64 SPARCL 64 confirmatory clinical 64 Intervention Effectiveness CATIE 64 Phase III AFFIRM 63 Val HeFT 63 HORIZONS AMI 63 ticagrelor Brilinta 63 Prostate AdenoCarcinoma Treatment 63 prospective multicentre 63 EXPLORE Xa 63 Multiple Ascending Dose 63 Initiate Phase II 63 multicentre randomized 63 ALSYMPCA 62 Trandolapril 62 Prospective Randomized 62 Phase III multicenter 62 BARI 2D 62 Phase III Pivotal 62 Phase Ib clinical 62 Edge STudy 62 Combination REOLYSIN R 62 Phase III Clinical Trial 62 ID NCT# 62 CATIE AD 62 APEX AMI trial 62 ongoing Phase IIIb 62 Bayer HealthCare Onyx Pharmaceuticals 62 RE LY ® 62 Multicenter Phase 62 BRIM3 62 Ovarian Cancer Screening 62 Outpatient Setting 62 multicenter prospective 62 ThermoDox ® clinical 62 placebo controlled clinical 61 Randomized Phase II 61 phase III ACCLAIM 61 TMC# C# 61 Initiates Phase II 61 ENDEAVOR IV 61 NO# [002] 61 phase IIb trial 61 Initiates Phase III 61 Prospective Multicenter 61 Refractory Angina 61 REMINYL ® 61 HCV SPRINT 61 registrational Phase 61 PROTECT AF 61 MEND CABG 61 Phase IIB 61 recurrent metastatic ovarian cancer 61 NABTT 61 STRIDE PD 61 HYVET 61 Aggressive Reduction 61 ADMIRE HF 61 Oral Insulin Capsule 61 randomized Phase III 61 placebo controlled Phase III 61 Carotid Revascularization Endarterectomy vs. 61 CHAMPION PCI 61 candidate CRLX# 61 Phase IIIb 61 Intervention Trial GAIT 61 pivotal bioequivalence 61 CLARITY TIMI 61 Sipuleucel T 61 Systemic Delivery 61 BCIRG 60 multicenter randomized controlled 60 Diamyd Medical Diamyd 60 Successfully Completes Phase 60 Dialysis Outcomes 60 pharmacogenomic translational research 60 Pivotal Trial 60 Patient Enrollment 60 Phase 1b Clinical Trial 60 RE MODEL 60 placebo controlled multicenter 60 LibiGel ® 60 BRIM2 60 substudy 60 EchoCRT 60 Medullary Thyroid Cancer 60 multicenter clinical 60 evaluating mipomersen 60 RE LY 60 First Patient Enrolled 60 Randomized Phase 60 Trial NLST 60 BrainGate TM 60 www.ClinicalTrials.gov 60 ILLUMINATE 60 Multicenter 60 Nicotine Vaccine 60 Microbicide 60 BR.# 60 ASTEROID 60 bazedoxifene conjugated estrogens 60 Phase IIIb clinical 60 prospective multicenter 60 Pre RELAX AHF 60 Initiates Phase 2b 60 #:#-#,# CrossRef Medline [001] 60 PRoFESS 60 PIX# [002] 60 DASISION 60 GCP compliant 60 Completes Patient Enrollment 60 EVEREST II 60 Truvada tablets 60 Confirmatory Phase 60 phase IIIb 59 Phase III Psoriasis 59 SUTENT ® 59 BiTE R 59 ADVANCE PD 59 Phase III Clinical Trials 59 neratinib 59 ToGA 59 SCD HeFT 59 Phase III Trial 59 STEP BD 59 Hedgehog Pathway Inhibitor 59 blinded randomized placebo controlled 59 tramiprosate Alzhemed TM 59 Cholesterol Levels SPARCL 59 Acute Ischemic Stroke 59 BOLDER II 59 Oral Fingolimod 59 FOLOTYN ® 59 International Verapamil SR 59 Hsp# Inhibitor 59 Phase III HEAT 59 Demonstrates Sustained 59 OLYMPIA registry 59 Heart Transplant Recipients 59 multicenter multinational 59 SPIRIT IV 59 Phase 1b trial 59 phase IIb clinical 59 Phase #b/#a clinical 59 Glufosfamide 59 Phase Ib IIa 59 ARBITER 6 59 ICON7 59 dose escalation clinical 59 STRATEGY FOR AN OPEN 59 ORAL Solo 59 landmark ATHENA 59 riociguat 59 EURIDIS 59 EMPOWER ™ 59 LUX Lung 59 CALERIE 59 multicenter Phase III 59 Achieves Primary Endpoint 59 NSABP B 59 Phase IIA 59 SPIRIT FIRST 59 Clinical Trial Data 59 PRESEPT 59 Phase III ThermoDox 59 phase IIa clinical 59 PREVENT IV 59 Glucosamine Chondroitin Arthritis 59 Breast Density 59 multicenter randomized placebo controlled 59 Multicenter Randomized 59 Meets Primary Endpoint 59 Digital Mammographic Imaging 59 multicentre randomized controlled 59 RIO Diabetes 59 IIa clinical 59 Hormone Refractory Prostate Cancer 59 AVERROES 59 VADT 59 LUMINATE 59 randomized multicenter 59 randomized controlled clinical 59 trastuzumab emtansine T DM1 59 Randomized Double Blind 59 deCODE AF TM 59 ONCONASE R 58 Abstract Accepted 58 HORIZONS AMI trial 58 rotary VAD 58 www.pranabio.com 58 Initiate Phase 58 Pivotal Phase 58 PARTNER Trial 58 DIRECT Trial 58 ACCORD Eye 58 Phase #b/#a 58 AIM HIGH 58 PRIMO CABG 58 REALITY Trial 58 TEC #OL 58 CAMMS# 58 Phase 1b clinical 58 STICH trial 58 DAPT Study 58 clinical pharmacology studies 58 placebo controlled randomized 58 Multicentre 58 fidaxomicin Phase 58 double blinded randomized 58 www.cancerconsultants.com 58 Immunotherapeutic 58 Randomized Double blind 58 sunitinib malate 58 cardio renal 58 fidaxomicin Phase 3 58 Therapeutic Arthritis 58 Safinamide 58 fosbretabulin 58 multicenter randomized clinical 58 ASCEND HF 58 treatment naive genotype 58 Dose Escalation 58 Acute Coronary Syndromes 58 APEX PD 58 SUCCEED trial 58 tolerability pharmacokinetics 58 Stent Thrombosis 58 Phase Forward InForm 58 programs visit http:/www.bionovo.com 58 Randomized Controlled Trials 58 SYMMETRY trial 58 THAT ARE DIFFICULT TO 58 Demonstrates Positive 58 Clinical Validation 58 Pivotal Phase III 58 KRN# 58 Phase 2b Study 58 Unstable Angina 58 Gastric Cancer 58 deforolimus 58 Therapeutic Antibody 58 Spine Patient Outcomes 58 Phase 2a Trial 58 Sequencing Systems 58 ClinicalTrials.gov 58 CEL SCI Phase III 58 TG MV 58 Ophena 58 Demonstrates Significant 58 Elagolix 58 phase IIb 58 Acute Myocardial Infarction 58 CRLX# 58 Screening Trial 58 Shows Promise Against 58 PD2i CA Cardiac Analyzer 58 Sapacitabine 58 Dose Ranging 58 Afatinib 58 oral PrEP 58 Left Ventricular Dysfunction 58 oral Janus kinase 58 Microplasmin 58 Raloxifene Evaluation MORE 58 RIO Lipids 58 evaluating tivozanib 58 Recurrent Glioblastoma 58 Maximum Tolerated Dose MTD 58 Denufosol 58 Cardiotoxicity 58 Nesiritide 58 Vaccine Immunology 58 Aortic Dissection 58 Pooled Analysis 58 rALLy clinical trial 57 Scandinavian Cardiac Outcomes 57 Raloxifene STAR 57 AVADO 57 prospective observational cohort 57 Randomized Study 57 induced macular edema 57 http:/www.clinicaltrials.gov 57 Schizophrenia Treatment 57 APPRAISE 57 ZYBRESTAT fosbretabulin 57 Motesanib 57 oral deforolimus 57 observational cohort study 57 please visit www.advaxis.com 57 ABSORB clinical 57 rALLy trial 57 Clinical Trial Enrollment 57 Pivotal Clinical Trial 57 Randomized Phase III 57 WHIMS 57 identifier NCT# 57 RE SURGE 57 CYT# potent vascular disrupting 57 methodologically rigorous 57 Clinical Trial Results 57 Temsirolimus 57 Randomized Evaluation 57 Prostate Cancer Prevention 57 VITAL Trial 57 National Emphysema Treatment 57 ANCHOR trial 57 Postmarketing 57 arzoxifene 57 evaluating satraplatin plus 57 Combination Treatment 57 Multicenter Automatic Defibrillator Implantation 57 Demonstrates Efficacy 57 Aplidin R 57 CURE AF 57 Lung Cancer Drug 57 NEVO RES 57 HPTN 57 orally inhaled migraine 57 Phase 2b Clinical Trial 57 PROactive study 57 IMPROVE HF 57 Relieve Depression 57 Pagoclone 57 pharmacodynamic effects 57 MIST II 57 Phase #/#a 57 multicenter placebo controlled 57 prospective randomized controlled 57 ACCOMPLISH 57 ORAL Sync 57 Randomized Trials 57 MAGE A3 ASCI 57 novel VDA molecule 57 Diabetic Neuropathy 57 AVOREN 57 Novel Oral 57 Enzastaurin 57 LEVADEX ™ 57 Tesmilifene 57 Randomised 57 interferon gamma 1b 57 staphylococcal vaccine 57 Clinical Outcome 57 TNFerade TM 57 phase IIa 57 randomized discontinuation 57 Myocardial Infarction Study 57 Trastuzumab DM1 57 By JENNIFER LEARN 57 EmbraceAC 57 PRE SURGE 57 randomized multicenter trial 57 MERLIN TIMI 57 Idenix Novartis 57 Phase lll 57 JAK Inhibitor 57 Lupus Drug 57 Clinicaltrials.gov 57 CIMZIA TM certolizumab pegol 57 Randomized Clinical Trials 57 Novel Antibiotic 57 Prostate Lung Colorectal 57 prospective observational 57 PROTEGE 57 Phase 2b Trial 57 phase IIb III 57 STEALTH C 57 HDL Selective Delipidation 57 #th Interscience Conference 57 Novo TTF 57 EMPOWER TM 57 controlled multicenter 57 Initiated Phase 57 evaluating REVLIMID 57 alvespimycin 57 NCIC CTG 57 ENGAGE AF TIMI 57 PRECISE 57 HCV NS5B polymerase 57 OPTIMIZE 57 MADIT II 57 Sibutramine Cardiovascular Outcomes 57 Tumor Response 57 #:#-#,# CrossRef Medline [002] 57 Treatment Shows Promise 57 phase Ib clinical 57 www.vivus.com 57 SIMPADICO 57 Prolongs Survival 57 Alpha Tocopherol Beta Carotene 57 CUSTOM III 57 ACUITY trial 57 Trial PCPT 57 ASPIRE HIGHER 57 Syllego system 57 PERSEUS 57 PROactive Study 57 Phase III ADT 57 Relapsed Multiple Myeloma 57 RE LY trial 57 randomized Phase IIb 57 ENDEAVOR III 57 Prostate Cancer Outcomes 57 Vaccine Adjuvant 57 designated HVTN 57 APTIVUS 57 placebo controlled dose escalation 57 Phase #/#a clinical 57 randomized discontinuation trial 57 biliary tract cancer 57 ECASS 57 Pirfenidone 57 #-# Full Text 57 PCI ExTRACT TIMI 56 IVR IWR 56 CTRC AACR San Antonio 56 Initiates Enrollment 56 See CLINICAL PHARMACOLOGY 56 multicentre 56 galiximab 56 SORT OUT III 56 ELCAP 56 Phase IIb Trial 56 Pertuzumab 56 acyclovir Lauriad R 56 RADIANT 56 Therapeutic Targets 56 Wisconsin Sleep Cohort 56 VALOR trial 56 Preclinical Study 56 Diabetic Macular Edema 56 mertansine 56 Treat Heart Failure 56 Advanced Melanoma 56 Ischemic Stroke 56 Maven Semantic 56 MelaFind pivotal 56 Nymox NX 56 NGFN 56 PFO migraine 56 Sorafenib HCC Assessment 56 Diabetic Foot Ulcer 56 Immune Tolerance Network 56 Immunomedics Announces 56 LungAlert TM 56 randomized clinical 56 Hedgehog Pathway 56 Quinamed 56 Commences Phase 56 Presents Preclinical 56 Screening Trial DMIST 56 multicenter trials 56 Serious Adverse Events 56 Multiethnic Study 56 Initiates Clinical Trial 56 Preclinical Models 56 randomized multicentre 56 Fingolimod 56 CLL8 56 Trial Initiative LSTI 56 MKC# MKC# PP 56 evaluating Actimmune 56 Protease Inhibitor 56 recurrent malignant glioma 56 IMPACT DCM 56 multicenter 56 nonrandomized 56 Lung Cancer Vaccine 56 Vascugel ® 56 ACRIN 56 Molecular Cancer 56 AAG geldanamycin analog 56 Selective Electrochemical Tumor Ablation 56 Analytical Method 56 Xelox 56 PRADAXA 56 randomized blinded 56 Initiate Clinical Trial 56 dose escalation phase 56 PI3K/Akt pathway inhibitor 56 MIVI III 56 Pivotal Study 56 PICSO ® 56 ALTTO 56 retrospective observational 56 Vaxfectin TM 56 multinational multicenter randomized 56 confirmatory Phase III 56 Metabolic Disorder 56 Rigorous scientific 56 DEEP AF 56 Severe Sepsis 56 MEND CABG II 56 thorough QT 56 PROSTVAC TM 56 Archexin 56 aldosterone antagonists 56 ILLUSTRATE 56 RenalGuard System TM 56 Polyp Prevention Trial 56 Transdermal Patch 56 endothelin antagonists 56 prospective multicenter study 56 label multicenter randomized 56 Myocet 56 Entereg TM 56 sapacitabine CYC# 56 Adjuvant Treatment 56 Study Evaluating 56 velafermin 56 optimal dosing 56 OpenNotes 56 Phase IIIb study 56 kidney urologic 56 Phase 2b kidney transplant 56 GOUT 56 Prostate Cancer Patients 56 R roscovitine 56 Phase IIIB IV 56 CINQUIL 56 PreCISe 56 malignant mesothelioma Alfacell 56 Clinical Trial Evaluating 56 Ophena TM 56 pharmacokinetic PK 56 Reduce Cardiovascular 56 RNAi Therapeutics 56 metastatic neuroendocrine tumors 56 HCV RESPOND 2 56 Carotid Stenting 56 INSPIRE Trial Phase III 56 Embolic Protection Device 56 pain palliation 56 Nasdaq IDRA today 56 DermaVir Patch 56 Phase Ib Clinical Trial 56 Fondaparinux 56 retinal vein occlusion induced 56 Medidata Designer 56 phase Ib 56 Vicriviroc 56 Gene Variation 56 Zemplar Capsules 56 Thorough QT 56 DU #b 56 Confirms Efficacy 56 Delcath Phase III 56 biostatistical analysis 56 Transdermal Delivery 56 Cardiac Resynchronization 56 Controlled Trial 56 iPrEx study 56 PHX# 56 Intervention Trial 56 AE# vaccine 56 medavis 56 AA Amyloidosis 56 R lenalidomide 56 Inhaled Insulin 56 CRESTOR #mg 56 recurrent glioma 56 CALGB # [001] 56 IMC #B 56 elotuzumab 56 LymphoStat B belimumab 56 Evaluation WISE 56 investigational protease inhibitor 56 Vaxfectin R 56 journal Gynecologic Oncology 56 FDA Approves Novel 56 prospective randomized multicenter 56 pharmacokinetic PK study 56 clevidipine 56 ARIXTRA R 55 evaluating carfilzomib 55 MGd 55 Glatiramer Acetate 55 randomized multicenter Phase III 55 PLCO 55 Subgroup Analysis 55 prospective randomized placebo 55 Inhaled Nitric Oxide 55 Investigational Drug 55 Vasogen Celacade 55 subanalysis 55 Silodosin 55 immunotherapeutic approaches 55 Septic Shock 55 molecular biomarkers 55 lintuzumab 55 Carotid Endarterectomy 55 HuMax EGFr 55 FOLFOX6 chemotherapy regimen 55 TAXUS ATLAS 55 Genetic Markers 55 relapsing remitting MS RRMS 55 WHEL 55 Cholesterol Lowering Drug 55 Intracerebral Hemorrhage 55 ABCSG 55 Syncria albiglutide 55 label multicenter 55 non nucleoside HCV 55 Asthma Intervention 55 EDEMA3 55 NICE SUGAR 55 Initiate Phase III 55 www.novartis.com 55 Val MARC 55 Phase III Trials 55 Phase III placebo controlled 55 Optical Coherence Tomography 55 cathepsin K inhibitor 55 Shows Promising 55 Azedra 55 Myocardial Perfusion Imaging 55 canagliflozin 55 Hematological 55 NP2 Enkephalin 55 TRANSCEND 55 RPGEH 55 TAXUS VI 55 HOPE TOO 55 HF ACTION 55 Trial Issue www.emagazine.com 55 Tykerb lapatinib 55 Adjuvant Colon Cancer 55 Proc Am Soc 55 prospective nonrandomized 55 Heterozygous Familial Hypercholesterolemia 55 Skin Lesions 55 Degarelix 55 Aurora kinase inhibitor 55 Phase III randomized 55 INS# [001] 55 GISSI 55 plus Copegus R 55 Suicidality 55 lorcaserin Phase 55 PRIMO CABG2 55 II Clinical Trial 55 includes TOLAMBA TM 55 Veracity ™ 55 Pafuramidine 55 recombinant PSMA vaccine 55 GRAVITAS trial 55 Bivalirudin 55 Preclinical Data 55 Antiviral Therapy 55 placebo controlled Phase 55 Proellex TM 55 HDAC Inhibitor 55 ZACTIMA 55 REACH Registry 55 CoFactor 55 PET FROM 55 Initiates Clinical 55 Patient Enrolment 55 LEVADEX TM 55 Teriflunomide 55 Therapeutic Effects 55 TriGrid 55 HuMax TAC 55 TRITON TIMI 55 IMPACT IMmunotherapy 55 MADIT 55 clinicaltrials.gov 55 Phase 2a Clinical Trial 55 MADIT CRT 55 Completes Enrollment 55 Decompensated Heart Failure 55 Anturol TM 55 multicentre prospective 55 IMA# 55 Adjuvant Breast Cancer 55 randomized Phase 2b 55 BMC Musculoskeletal Disorders 55 SAR# [004] 55 ONTARGET R 55 Long Lesion 55 florbetaben 55 Acute Decompensated Heart Failure 55 ORACLE MS 55 ADVANCE ILLUMINATE 55 Double Blind Placebo 55 Shows Efficacy 55 ANN INTERN MED 55 opioid naive 55 Stenting Trial CREST 55 forodesine 55 www.clinicaltrials.gov 55 tanespimycin 55 S#.# [006] 55 ASCO GI 55 Therapeutic Efficacy 55 AVN# Phase 55 Biomarker Study 55 RSD# oral 55 CAPACITY trials 55 NATRECOR ® 55 Platelet Inhibition 55 sorafenib tablets 55 Chronic Heart Failure 55 Max Neeman International 55 Rotavirus Vaccine 55 MEK Inhibitor 55 label multicenter Phase 55 multicenter randomized 55 Am J Geriatr 55 torcetrapib atorvastatin 55 rhLF 55 Oral Insulin 55 relapsed MM 55 AACR San Antonio 55 Universal Flu Vaccine 55 #rd Annual CTRC 55 RESOLUTE clinical 55 Oral NKTR 55 AEGR 55 RECORD1 55 Teva Provides Update 55 TO AVOID PREGNANCY WHILE 55 eTag assays 55 Active Ulcerative Colitis 55 Ranolazine 55 Corlux 55 Tolvaptan 55 Orazol 55 Zenvia Phase III 55 Urocortin 2 55 GW# [003] 55 Randomized Clinical Trial 55 iPrEx 55 Lancet Oncology journal 55 pharmacokinetics pharmacodynamics 55 TB Vaccine 55 Drug Shows Promise 55 APEX AMI 55 Evidence Therapeutic 55 PROactive 55 Treating Chronic 55 Treating Depression 55 Brain Scans 55 AIR2 Trial 55 MTWA testing 55 RELOVAIR ™ 55 Diamyd R 55 Phase 1a 55 ENVISION 55 CardioFit 55 trials RCTs 55 Glybera R 55 JAK inhibitor 55 Cardiac Allograft Rejection 55 Renal Cancer 55 YONDELIS 55 Improves Survival 55 trastuzumab DM1 T DM1 55 toenail onychomycosis 55 PHASE III 55 enzastaurin 55 prospective longitudinal 55 TLK# 55 UNLOAD 55 ONCOLOGY 55 Renal Cell Carcinoma RCC 55 Huggins Cams Time 55 OncoVex 55 Protein Expression 55 paclitaxel poliglumex 55 Pivotal Trials 54 Mg Usa 54 Investigator Initiated 54 PERISCOPE 54 Risk Stratification 54 tipranavir 54 Therapy Reduces 54 efficacy tolerability 54 RhuDex 54 Virtual Histology 54 Drug Candidate 54 dependent kinase inhibitor 54 chronic myocardial ischemia 54 Pharmacokinetic Study 54 AEG# 54 torezolid phosphate 54 NCCTG 54 Randomised Controlled Trial 54 olaparib 54 trial evaluating PRX# 54 ConclusionThis 54 JAK2 inhibitor 54 Vitaxin 54 delipidation 54 longitudinal cohort study 54 multicenter phase 54 Gynecologic Oncology Group 54 Hepatocellular Carcinoma 54 Cites Positive 54 Tyrima 54 GERD migraine headaches 54 Avian Flu Vaccine 54 ENABLE Phase 2 54 PRESENTED AT 54 Coronary Revascularization 54 FLUPAN 54 Anticancer Activity 54 Phase III VISTA 54 TAXUS IV 54 Lilly Alkermes 54 Rilonacept 54 Prodarsan R 54 Carotid Artery Stenting 54 observational cohort 54 YOUR LOCAL ANIMAL SHELTER 54 PREDICTIVE 54 CALGB # [002] 54 Anti CD# Antibody 54 Cimzia TM 54 Bosutinib 54 Health Initiative WHI 54 p# biomarker 54 NCT# ClinicalTrials.gov 54 Pharmaprojects 54 controlled multicenter Phase 54 LibiGel Phase III 54 Initiates Clinical Trials 54 Phase 2a preventative 54 ASCO GU 54 multicenter study 54 Kosan dependence 54 lorvotuzumab mertansine 54 budesonide foam 54 Current Controlled Trials 54 dirucotide MBP# 54 Seconds Count 54 PANVAC VF 54 Submits NDA 54 oral prodrug 54 orBec 54 Acute Liver Failure 54 ASSERT 54 Antitumor Activity 54 USpella 54 PRECiSE 54 randomized controlled Phase 54 Allovectin 7 ® 54 Phase 1b clinical trials 54 quinacrine 54 blinded randomized 54 VESTASYNC 54 AOD# [002] 54 Placebo Controlled Trial 54 Predict Risk 54 TOLAMBA 54 Glucosamine chondroitin Arthritis 54 Phase IIa Clinical Trial 54 Ambrisentan 54 www.ilgenetics.com 54 Vertebral Fracture 54 Phase IIb Clinical Trial 54 Eluting Stent 54 clinical trial 54 preclinical efficacy 54 IT HARD TO 54 farletuzumab 54 trodusquemine 54 selenium supplementation 54 First Patient Dosed 54 Lung Cancer Screening 54 Rheos System 54 Tyrosine Kinase Inhibitor 54 Pulmonary Arterial Hypertension 54 ATAC Arimidex Tamoxifen Alone 54 oral rivaroxaban 54 www.sematech.org 54 CYP#A# CYP#D# 54 Pimavanserin 54 ThermoDox R 54 Uterine Fibroid Embolization 54 Late Breaker 54 SABCS 54 PROSTVAC ® 54 Ovarian PLCO Cancer 54 label dose escalation 54 rectal microbicide 54 randomized controlled 54 FDA APPROVES 54 HIV HCV coinfected 54 EGIR 54 GISSI HF 54 endometriosis ovarian cysts 54 EuroIntervention 54 Drug Fails 54 Hepatotoxicity 54 ERYtech 54 Long Term Efficacy 54 STOP AF 54 Lung Injury 54 CTAP# Capsules 54 unique alkylating agent 54 Resurgex Plus R 54 PRIALT 54 Antibody Discovery 54 REVIVE Diabetes 54 pregabalin Lyrica 54 Zoraxel 54 Lung Cancer Trial 54 SANTE 54 Adverse Event 54 HER2 Positive Breast Cancer 54 Clinical Study 54 #:#-#,# [003] 54 including eniluracil ADH 54 Observational Study 54 Aggressive Drug Evaluation 54 ongoing Phase 1b 54 CLOTS 54 BARACLUDE R 54 demonstrated clinically meaningful 54 PD2i CA 54 RG# ITMN 54 TM Drug Eluting 54 Presents Preclinical Data 54 ATTRACT 54 CONQUER OB 54 TAXUS TM 54 specific CCR9 antagonist 54 clinicaltrials 54 InForm ITM 54 Receives CE Marking 54 GAMMAGARD 54 Patients Treated With 54 Newly Diagnosed Multiple Myeloma 54 Genasense ® oblimersen 54 Brentuximab Vedotin SGN 54 Phase IIb trials 54 Malaria Vaccine 54 surveys Herbenick 54 PROVENGE ® 54 Treatment Outcome 54 Cancer Incidence Mortality 54 dose escalation Phase 54 Nuvelo Announces 54 Insulin Sensitivity 54 epoetin zeta 54 Candesartan 54 EHT AGN 54 ACTIVE W 54 Evidence Therapeutic study 54 XIENCE V Stent System 54 myopic CNV 54 Cervical Dysplasia 54 www.ingenuity.com 54 PEARL SC 54 Xanafide 54 eprotirome 54 vidofludimus 54 Complicated Skin 54 http:/www.vivus.com 54 Intra Arterial 54 TRANSFORMS 54 bicifadine 54 Phase Ib 54 Node Positive 54 TASKi3 54 Exelixis compounds 54 Phase III confirmatory 54 Reduces Mortality 54 Study Shows Benefits 54 biochemical profiling 54 RE COVER 54 Dapagliflozin 54 vosaroxin 54 Fabry Disease 54 davunetide intranasal AL 54 R rosiglitazone maleate 54 Urgent Intervention Triage 54 oral FTY# 54 Cloretazine 54 investigational pan BCR 54 CombAT study 54 CLARITY study 54 genomewide association study